HomeSearchCancer Gene Therapy

Cancer Gene Therapy

Springer Nature · United States · Est. 1992

ISSN1476-5500
SJR Q1WOS SCIEScopus / SJR
Impact Factor & Quartile · Web of Science (JCR)

✓ Indexed in the Web of Science Core Collection (SCIE) — Clarivate publishes an official Journal Impact Factor and JCR quartile for this journal.

See the official Impact Factor & quartile on the journal’s page ↗

The Impact Factor & JCR quartile are licensed by Clarivate — we link you to the official source instead of reprinting a number that can go out of date. Open metrics below: SCImago Q1. Source: Clarivate Journal Citation Reports.

📊 Standing in its field
Where this journal ranks among others in the same subject area.
Q1
SJR · Scopus
Top 25% in field
Clarivate’s JCR quartile is a separate ranking and may differ
SJR Scorei
1.749
H-Indexi
111
SNIPi
0.961
Total Worksi
2,971
Total Citationsi
89,422
2yr Mean Citednessi
6.13
Open Impact Factor alternative
Retractions
32
Source: Retraction Watch

Aims & Scope

Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. The journal publishes original laboratory and clinical research papers, case reports and review articles. Publication topics include RNAi approaches, drug resistance, hematopoietic progenitor cell gene transfer, cancer stem cells, cellular therapies, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA & ribozymes), apoptosis; mechanisms and therapies, vaccine development, immunology and immunotherapy, DNA synthesis and repair. Cancer Gene Therapy publishes the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene transfer/gene therapy and cellular therapies as applied to cancer research. Types of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensitivity, gene therapy, cellular therapy, tumor suppressor and anti-oncogene therapy, cytokine/tumor immunotherapy, etc.; industry perspectives; and letters to the editor.

General Information

Country / RegionUnited States
Primary LanguageEnglish
1st Year Published1992
FrequencyTwelve No. A Year, 2000-
StatusActive (last: 2026)
Total Publications2,971
Publisher OrgSpringer Nature
Visit Journal Website

Submission Info

Peer Review
OA License
OA Rate

Ethics & Quality

COPE Member✗ No
OASPA Member✗ No
Not on Predatory Lists✓ Yes
Plagiarism Detection✓ Yes

Think.Check.Submit Compliance

7/11 · 64%
Do you know the journal / publisher?
Springer Nature
Does the journal have a website?
✓ Linked
Is the ISSN verified?
1476-5500
Indexed in a trusted database?
WoS, Scopus
Peer review process documented?
N/A
Follows ethical publishing standards (COPE)?
N/A
Not on predatory/blacklists?
✓ Clean
Long-term digital preservation?
N/A
Plagiarism detection in place?
Yes
Listed in DOAJ (verified OA)?
N/A
Primary language documented?
English

A twelfth criterion — whether APC fees are clearly disclosed — is not scored here; it is left out of the total rather than counted as a failure. Publication charges appear in the metrics card above.

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Publication & Citation Trend

Articles published
Citations received
87
2.7k
2019
111
4.4k
2020
137
4.1k
2021
170
3.1k
2022
140
2.1k
2023
146
2k
2024
130
489
2025
78
35
2026

Source: OpenAlex · Each year’s green bar = citations earned by that year’s papers, counted to date — so recent years look lower simply because their papers haven’t had time to be cited yet.

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.

Molecular BiologyQ1
Molecular MedicineQ1
Cancer ResearchQ2

Subject Classification

Web of Science Categories

Biotechnology & Applied MicrobiologyGenetics & HeredityMedicine, Research & ExperimentalOncology

Scopus Categories

Cancer ResearchMolecular MedicineMolecular Biology

Research Topics (OpenAlex)

Virus-based gene therapy researchRNA Interference and Gene DeliveryCAR-T cell therapy researchImmunotherapy and Immune ResponsesCancer Research and TreatmentsCancer-related molecular mechanisms researchMicroRNA in disease regulationRNA modifications and cancerViral Infectious Diseases and Gene Expression in InsectsImmune Cell Function and Interaction

Frequently asked questions about Cancer Gene Therapy

Is Cancer Gene Therapy a predatory journal?

PubScope has no integrity flags on record for Cancer Gene Therapy: it is indexed in Web of Science, Scopus, and is not on DOAJ's withdrawn list. Indexing is a transparency signal, not a guarantee — always confirm fit and policies before submitting.

What is the impact factor of Cancer Gene Therapy?

Cancer Gene Therapy is indexed in the Web of Science Core Collection, so Clarivate publishes an official Journal Impact Factor for it (since the 2023 Journal Citation Reports, every Core Collection journal — including Arts & Humanities and Emerging Sources titles — receives one). PubScope links to Clarivate's official source rather than reprinting the number, which can be out of date. Its open 2-year mean citedness is 6.13.

Is Cancer Gene Therapy indexed in Scopus and Web of Science?

Cancer Gene Therapy is indexed in Web of Science, Scopus.

What is the aims and scope of Cancer Gene Therapy?

Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. The journal publishes original laboratory and clinical research papers, case reports and review articles. Publication topics include RNAi approaches, drug resistance, hematopoietic progenitor cell gene transfer, cancer stem cells, cellular therapies, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, can

Compare This JournalFind Similar← Back to Search
Understand these signals
How to tell if a journal is predatoryWhat Q1–Q4 quartiles meanWeb of Science vs Scopus vs DOAJWhat is an APC?

Data updated: 2026-05-22 · Sources: SJR, DOAJ, OpenAlex, WoS, Crossref